15 Stocks That Insiders Won't Stop Buying - 15 of 15 Slide 15Back to 14Next Slideshow Back to 14Next Slideshow Avadel Pharmaceuticals (NASDAQ:AVDL)Dollar Amount of Shares Purchased $526,363.04Number of Insider Purchases in the Last 180 Days 8Volume of Shares Purchased 55,579Who Bought Shares Geoffrey Michael Glass (Director), Gregory J Divis (CEO), Linda Palczuk (Director), Peter J Thornton (Director) and Thomas S Mchugh (CFO)About Avadel PharmaceuticalsAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. More about Avadel Pharmaceuticals More Investing Slideshows:7 High-Growth Stocks Under $107 Dividend Stocks That Show Why Cash Is King7 Stocks to Buy as Esports Goes Mainstream7 Silver Stocks Set to Sizzle on Higher DemandProfit Without Panic: 7 ETFs to Diversify Your Portfolio7 Flying Car Stocks to Buy Before the Sector Really Takes Off7 Uranium Stocks That Can Fuel a Growth Portfolio7 Growth Stocks Positioned for Further Growth7 Defensive Stocks to Shield Your Portfolio from Inflation7 Stocks Under $20 That Could Double Your MoneySlide 15Back to 14Next Slideshow More From MarketBeatElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored7 Sensational Small-Cap Stocks Set for Big GainsThe Russell 2000 Index is up more than 40% in the last 12 months. This is an index that tracks the performance...MarketBeatThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored15 Healthcare Stocks that Analysts Love in a Post-Pandemic WorldThere are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutica...MarketBeatA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored7 Infrastructure Stocks to Buy Like There's No TomorrowMembers of Congress agree on very few things. But in the last four years, there has been bipartisan support fo...MarketBeat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Slide 15Back to 14Next Slideshow Back to 14Next Slideshow Avadel Pharmaceuticals (NASDAQ:AVDL)Dollar Amount of Shares Purchased $526,363.04Number of Insider Purchases in the Last 180 Days 8Volume of Shares Purchased 55,579Who Bought Shares Geoffrey Michael Glass (Director), Gregory J Divis (CEO), Linda Palczuk (Director), Peter J Thornton (Director) and Thomas S Mchugh (CFO)About Avadel PharmaceuticalsAvadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. More about Avadel Pharmaceuticals More Investing Slideshows:7 High-Growth Stocks Under $107 Dividend Stocks That Show Why Cash Is King7 Stocks to Buy as Esports Goes Mainstream7 Silver Stocks Set to Sizzle on Higher DemandProfit Without Panic: 7 ETFs to Diversify Your Portfolio7 Flying Car Stocks to Buy Before the Sector Really Takes Off7 Uranium Stocks That Can Fuel a Growth Portfolio7 Growth Stocks Positioned for Further Growth7 Defensive Stocks to Shield Your Portfolio from Inflation7 Stocks Under $20 That Could Double Your MoneySlide 15Back to 14Next Slideshow More From MarketBeatElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored7 Sensational Small-Cap Stocks Set for Big GainsThe Russell 2000 Index is up more than 40% in the last 12 months. This is an index that tracks the performance...MarketBeatThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored15 Healthcare Stocks that Analysts Love in a Post-Pandemic WorldThere are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutica...MarketBeatA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored7 Infrastructure Stocks to Buy Like There's No TomorrowMembers of Congress agree on very few things. But in the last four years, there has been bipartisan support fo...MarketBeat
